{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:04Z","timestamp":1789556404767,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jns.2025.123727","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:32:40Z","timestamp":1760499160000},"page":"123727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study"],"prefix":"10.1016","volume":"478","author":[{"given":"Mar\u00eda Agustina","family":"Piedrabuena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Fiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Marrodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Agustina","family":"Z\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Heriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerem\u00edas","family":"Ayerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"M\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Pita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Adri\u00e1n","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Balbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Nadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Liwacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Luetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Casales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Hryb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Leguizam\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima Pagani","family":"Cassar\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Celica","family":"Ysrraelit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.123727_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2025.123727_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.123727_bb0015","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2025.123727_bb0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","article-title":"Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region","volume":"80","author":"Hittle","year":"2023","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.123727_bb0025","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s10072-023-06794-w","article-title":"Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis","volume":"44","author":"Nabizadeh","year":"2023","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2025.123727_bb0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2025.123727_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.123727_bb0040","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.jns.2025.123727_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.123727_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14737175.2021.1886082","article-title":"Considering patient age when treating multiple sclerosis across the adult lifespan","volume":"21","author":"Jakimovski","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"9","key":"10.1016\/j.jns.2025.123727_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102893","article-title":"Immunosenescence in multiple sclerosis: the identification of new therapeutic targets","volume":"20","author":"Dema","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2025.123727_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102815","article-title":"Multiple sclerosis and aging: comorbidity and treatment challenges","volume":"50","author":"Ostolaza","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123727_bb0065","doi-asserted-by":"crossref","first-page":"1207617","DOI":"10.3389\/fneur.2023.1207617","article-title":"Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review","volume":"14","author":"Capasso","year":"2023","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.123727_bb0070","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2025.123727_bb0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2025.123727_bb0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123727_bb0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2025.123727_bb0090","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420969016","article-title":"Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2025.123727_bb0095","doi-asserted-by":"crossref","first-page":"P262","DOI":"10.1016\/j.msard.2018.10.097","article-title":"Cladribine tablets 35 mg\/kg is efficacious in patients aged above and below 45 years with relapsing multiple sclerosis in the clarity study","volume":"26","author":"Giovanonni","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2025.123727_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/20552173251321810","article-title":"European experience of cladribine tablets in elderly patients with multiple sclerosis: could it be the last treatment?","volume":"11","author":"de Seze","year":"2025","journal-title":"Multiple Scleros. J. Exp. Transl. Clin."},{"issue":"78","key":"10.1016\/j.jns.2025.123727_bb0105","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review\u2730","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2025.123727_bb0110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/ijms26030884","article-title":"A window into new insights on progression independent of relapse activity in multiple sclerosis: role of therapies and current perspective","volume":"26","author":"Guerra","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.123727_bb0115","article-title":"The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation","volume":"12","author":"Guerra","year":"2025","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2025.123727_bb0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative review on the use of Cladribine tablets as exit therapy for stable elderly patients with multiple sclerosis","volume":"13","author":"De Seze","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2025.123727_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106625","article-title":"Exit strategies in patients with stable MS: cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine","author":"Versteegh","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123727_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763433","article-title":"Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets","volume":"12","author":"Giovannoni","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25003478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25003478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T05:04:20Z","timestamp":1764047060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25003478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"alternative-id":["S0022510X25003478"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123727","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123727"}}